Publications by authors named "D Prisco"
Introduction: The recently published ACR/EULAR classification criteria score (3 points or more) both clinical and laboratory criteria to define the presence of antiphospholipid syndrome (APS). The clinical criteria have been better defined while laboratory criteria remain the same [lupus anticoagulant (LA), anticardiolipin (aCL) and anti ß2-Glycoprotein I (aß2GPI) antibodies] but with different impact (points) on the classification of patients. APS is excluded if more than 3 years separate positive test for antiphospholipid antibodies (aPL) and clinical manifestation.
View Article and Find Full Text PDFArticle Synopsis
- Frailty affects how well anticoagulant therapy works for patients with atrial fibrillation (AF), and the age-weighted Charlson comorbidity index may help assess risks in these patients treated with direct oral anticoagulants (DOACs).
- In a sub-analysis of the MAS trial, researchers compared dosing based on the Charlson index with standard criteria and examined its impact on adverse events.
- While the Charlson index influenced dosing decisions, it did not improve the prediction of adverse events in AF patients, indicating that the standard approach remains valid.
Article Synopsis
- * Different PTMs like glycosylation and oxidation can alter the structure and properties of fibrinogen, influencing clot density and stability, especially in conditions like diabetes and oxidative stress.
- * The review explores current research on fibrinogen PTMs, their specific effects on clot formation and breakdown, and their potential implications for treating thrombotic disorders.
Background: The MAS study (Blood Advances 2024) showed that a high proportion of Italian AF patients treated with direct oral anticoagulants (DOACs) receive reduced doses. This sub-analysis of MAS data aimed to analyze the effects of reduced (appropriate or not)- or standard-dose use on DOAC activity assessed at baseline and the occurrence of thrombotic or bleeding complications during follow-up.
Methods: The MAS study design, the methods for DOAC measurement, the results, and the adverse events during follow-up, are described in detail elsewhere.
Stroke is one of the most common causes of mortality and disability worldwide. Antithrombotic therapy represents the mainstay in primary and secondary prevention, both in cardioembolic and non-cardioembolic stroke. Particularly, direct oral anticoagulants play a crucial role in atrial fibrillation, the most common cause of cardioembolic stroke, whereas single or dual antiplatelet therapy is preferred in non-cardioembolic stroke.
View Article and Find Full Text PDF